Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Large Drop in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 70,200 shares, a decrease of 16.9% from the February 28th total of 84,500 shares. Based on an average trading volume of 415,800 shares, the short-interest ratio is presently 0.2 days. Approximately 2.6% of the company’s shares are short sold.

Theriva Biologics Price Performance

Shares of NYSEAMERICAN TOVX traded down $0.02 during midday trading on Thursday, reaching $1.16. 9,179 shares of the company’s stock were exchanged, compared to its average volume of 994,939. The stock’s fifty day moving average price is $1.36. The company has a market capitalization of $3.22 million, a PE ratio of -0.04 and a beta of 1.22. Theriva Biologics has a 52-week low of $1.03 and a 52-week high of $12.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned approximately 6.13% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.